In ER+ and luminal breast cancer cells, pathological level of estrogen in serum and tissue fluids promote carcinogenesis and tumor growth by decreasing SELENBP1 expression, subsequently abolishing the anti-tumor effect of selenium. Here, SELENBP1 is linked to breast cancer.